{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T13:57:23Z","timestamp":1777557443823,"version":"3.51.4"},"reference-count":28,"publisher":"SAGE Publications","issue":"11","license":[{"start":{"date-parts":[[2019,10,21]],"date-time":"2019-10-21T00:00:00Z","timestamp":1571616000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,10,21]],"date-time":"2019-10-21T00:00:00Z","timestamp":1571616000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Technology &amp; Therapeutics"],"published-print":{"date-parts":[[2019,11]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Titration of basal insulin led by either the physician or the patient is not well understood in India. This analysis of Indian subset of Asian Treat to Target Lantus Study (ATLAS) compared effectiveness of patient-led with physician-led titration of once-daily insulin glargine 100\u2009U\/mL (Glargine-U-100) in patients with type 2 diabetes mellitus (T2DM) uncontrolled on oral antidiabetes drug (OAD).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>In this open-label parallel group study, randomized patients (either physician-led or patient-led [self-titration] group) followed the same dose titration algorithm (fasting blood glucose [FBG] target 110\u2009mg\/dL [6.1\u2009mmol\/L]). The primary endpoint was change in mean glycated hemoglobin (HbA1c) at week 24 in the patient-led group versus the physician-led group.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Patients (40\u201375 years) were randomized to either the physician-led group (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      \u2009=\u200939) or the patient-led group (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      \u2009=\u200936). At week 24, self-titration led to a greater decline in HbA1c than physician-led titration (\u22121.3% vs. \u22121.1%). Mean decrease in FBG was more in the patient-led group than in the physician-led group (\u221253.7\u2009mg\/dL vs. \u221235.5\u2009mg\/dL). Mean daily dose of Glargine-U-100 at week 24 was higher in the patient-led group than in the physician-led group (30.0\u2009U vs. 23.8\u2009U). At any time during the study, 30.6% and 7.7% of patients in the patient-led and physician-led groups, respectively, showed target HbA1c level of &lt;7.0% without severe hypoglycemia. Treatment satisfaction and quality of life improved in both groups. Overall, treatment was safe and well tolerated, and none of the events led to treatment discontinuation.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Patient-led adjustment of Glargine-U-100 in outpatient setting can be a safe and effective method for glycemic control in Indian patients with T2DM uncontrolled on OADs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1089\/dia.2019.0037","type":"journal-article","created":{"date-parts":[[2019,7,23]],"date-time":"2019-07-23T16:11:14Z","timestamp":1563898274000},"page":"656-664","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":9,"title":["Effectiveness and Safety of Physician-Led Versus Patient-Led Titration of Insulin Glargine in Indian Patients with Type 2 Diabetes Mellitus: A Subanalysis of the Asian Treat to Target Lantus Study (ATLAS)"],"prefix":"10.1177","volume":"21","author":[{"given":"Anoop","family":"Misra","sequence":"first","affiliation":[{"name":"Fortis-C-DOC Centre of Excellence for Diabetes, Metabolic Diseases and Endocrinology, New Delhi, India."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mayur","family":"Patel","sequence":"additional","affiliation":[{"name":"All India Institute of Diabetes and Research, Swasthya Diabetes Care, Jay Mangal Society, Ahmedabad, India."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pankaj","family":"Agarwal","sequence":"additional","affiliation":[{"name":"Hormone Care and Research Centre SB-5, Ghaziabad, India."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sailesh","family":"Lodha","sequence":"additional","affiliation":[{"name":"Dear Foundation, Jaipur, India."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikhil","family":"Tandon","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, 3rd Floor Biotechnology Block, AIIMS, New Delhi, India."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohan","family":"Magdum","sequence":"additional","affiliation":[{"name":"Jehangir Clinical Development Pvt. Ltd., Jehangir Hospital, Pune, India."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chittaranjan","family":"Yajnik","sequence":"additional","affiliation":[{"name":"Diabetes Unit, KEM hospital Research Centre, Pune, India."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Romik","family":"Ghosh","sequence":"additional","affiliation":[{"name":"Medical Affairs Department, Sanofi, Mumbai, India."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ajit","family":"Walekar","sequence":"additional","affiliation":[{"name":"Clinical Study Unit, Sanofi, Mumbai, India."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2019,10,21]]},"reference":[{"key":"e_1_3_5_2_2","unstructured":"IDF Diabetes Atlas 2017: www.diabetesatlas.org\/resources\/2017-atlas.html (accessed August1 2018)."},{"key":"e_1_3_5_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0806359"},{"key":"e_1_3_5_4_2","doi-asserted-by":"publisher","DOI":"10.2337\/diaclin.27.2.60"},{"key":"e_1_3_5_5_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc14-2441"},{"key":"e_1_3_5_6_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmjdrc-2016-000270"},{"issue":"4","key":"e_1_3_5_7_2","first-page":"146S","article-title":"Psychological insulin resistance: overcoming barriers to starting insulin therapy","volume":"32","author":"Davis SN","year":"2006","unstructured":"Davis SN, , Renda SM: Psychological insulin resistance: overcoming barriers to starting insulin therapy. Diabetes Educ, 2006; 32 Suppl 4:146S\u2013152S.","journal-title":"Diabetes Educ"},{"key":"e_1_3_5_8_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0036361"},{"key":"e_1_3_5_9_2","doi-asserted-by":"publisher","DOI":"10.1177\/0145721711432649"},{"key":"e_1_3_5_10_2","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.29.01.06.dc05-1058"},{"key":"e_1_3_5_11_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2007.00804.x"},{"key":"e_1_3_5_12_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc07-2137"},{"key":"e_1_3_5_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2009.01060.x"},{"key":"e_1_3_5_14_2","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.28.6.1282"},{"key":"e_1_3_5_15_2","doi-asserted-by":"publisher","DOI":"10.4158\/EP14079.OR"},{"key":"e_1_3_5_16_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc11-2021"},{"key":"e_1_3_5_17_2","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2010.0170"},{"key":"e_1_3_5_18_2","doi-asserted-by":"publisher","DOI":"10.2147\/DMSO.S104752"},{"key":"e_1_3_5_19_2","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12053"},{"key":"e_1_3_5_20_2","first-page":"32","article-title":"Centralized treatment allocation in comparative clinical trials","volume":"9","author":"Buyse M","year":"2000","unstructured":"Buyse M: Centralized treatment allocation in comparative clinical trials. Appl Clin Trials, 2000; 9:32\u201337.","journal-title":"Appl Clin Trials"},{"key":"e_1_3_5_21_2","first-page":"111","volume-title":"Handbook of Psychology and Diabetes: A Guide to Psychological Measurement in Diabetes Research and Practice","author":"Bradley C","year":"1994","unstructured":"Bradley C. (1994) The Diabetes Treatment Satisfaction Questionnaire: DTSQ. In: Bradley C., Ed., Handbook of Psychology and Diabetes: A Guide to Psychological Measurement in Diabetes Research and Practice, Harwood Academic Publishers, Chur, 111\u2013132."},{"key":"e_1_3_5_22_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008921419108"},{"key":"e_1_3_5_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/0168-8510(90)90421-9"},{"key":"e_1_3_5_24_2","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.26.11.3080"},{"key":"e_1_3_5_25_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-5491.2006.01881.x"},{"key":"e_1_3_5_26_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc06-1357"},{"key":"e_1_3_5_27_2","doi-asserted-by":"publisher","DOI":"10.4158\/EP151126.CS"},{"key":"e_1_3_5_28_2","first-page":"S42","article-title":"Premix insulin: initiation and continuation guidelines for management of diabetes in primary care","volume":"57","author":"Indian National Consensus Group","year":"2009","unstructured":"Indian National Consensus Group: Premix insulin: initiation and continuation guidelines for management of diabetes in primary care. J Assoc Physicians India, 2009; 57:S42\u2013S46.","journal-title":"J Assoc Physicians India"},{"key":"e_1_3_5_29_2","doi-asserted-by":"publisher","DOI":"10.4103\/2230-8210.104120"}],"container-title":["Diabetes Technology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/dia.2019.0037","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/dia.2019.0037","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/dia.2019.0037","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T18:18:17Z","timestamp":1777400297000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/dia.2019.0037"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,21]]},"references-count":28,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["10.1089\/dia.2019.0037"],"URL":"https:\/\/doi.org\/10.1089\/dia.2019.0037","relation":{},"ISSN":["1520-9156","1557-8593"],"issn-type":[{"value":"1520-9156","type":"print"},{"value":"1557-8593","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,21]]}}}